Generate Biomedicines and Zealand Pharma Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic Diseases
Generate Biomedicines official news-release RSS · 行業原文收錄 · 來源發佈:Tue Oct 13 2026 20:30:00 GMT+0000 (Coordinated Universal Time) · 本站收錄:Tue Oct 13 2026 21:08:11 GMT+0000 (Coordinated Universal Time)
已保存的原文節選
Collaboration will combine Zealand Pharma’s expertise in metabolic health with Generate’s proprietary generative AI platform to create multispecific drug candidates with tailored biological functions Generate will receive $30M upfront, up to $35M in early preclinical milestones, and a total of up to $1.2B in milestones, plus tiered royalties for two initial programs, with an option to add a third
以上為帶出處的原文節選,完整內容請閱讀原始鏈接。自動收錄與主題分類不等於事實核驗。